FindTrial
Sign In

NovoTTF-100L(O)

DEVICE2 trials

Sponsors

NovoCure Ltd.

Conditions

Ovarian CancerOvarian Carcinoma

Phase 1

Safety, Feasibility and Effect of TTFields (200 kHz) Concomitant With Weekly Paclitaxel in Recurrent Ovarian Carcinoma (INNOVATE)
NCT02244502
NovoCure Ltd.Ovarian Carcinoma
Start: 2014-09-30End: 2016-12-31Updated: 2016-09-21

Phase 3

Effect of Tumor Treating Fields (TTFields, 200 kHz) Concomitant With Weekly Paclitaxel for the Treatment of Recurrent Ovarian Cancer (ENGOT-ov50 / GOG-3029 / INNOVATE-3)
CompletedNCT03940196
NovoCure Ltd.Ovarian Cancer
Start: 2019-03-22End: 2023-05-18Updated: 2024-03-29

Related Papers

Tumor Treating Fields (TTFields) Therapy in Unresectable Pleural Mesothelioma: Overview of Efficacy, Safety, and Future Outlook.
2025-04-23
Clinical Trial Protocol for ROSELLA: a phase 3 study of relacorilant in combination with nab-paclitaxel versus nab-paclitaxel monotherapy in advanced platinum-resistant ovarian cancer.
2024-07-015 citations
#1350 Tumor treating fields (TTFields) therapy in platinum-resistant ovarian cancer: results from the ENGOT-ov50/GOG-3029/INNOVATE-3 phase 3 study
2024-03-013 citations
#471 PARP-inhibitors can be applied together with tumor treating fields (TTFields) to prolong survival in an ovarian cancer mouse model
2023-09-01
403 Phase 3 trial of tumor treating fields concomitant with weekly paclitaxel for platinum-resistant ovarian cancer: ENGOT-OV50/GOG-329/INNOVATE-3
2020-12-01
358 Phase 3 trial of tumor treating fields concomitant with weekly paclitaxel for platinum-resistant ovarian cancer: ENGOT-ov50/GOG-329/INNOVATE-3
Poster2020-11-011 citations
176 Evaluating the safety of tumor treating fields (TTFields) application to the torso – in vivo studies
Regular and Young Investigator Award Abstracts2020-11-011 citations
P154 Tumor treating fields (200 kHz) concomitant with weekly paclitaxel for platinum-resistant ovarian cancer: phase 3 INNOVATE/ENGOT-ov50 study
2019-11-011 citations
Abstract CT174: Phase III INNOVATE study of tumor treating fields (200 kHz) concomitant with weekly paclitaxel for platinum-resistant ovarian cancer (ENGOT-ov50/BGOG study groups)
Cancer Research2019-07-011 citations
Abstract CT174: Phase III INNOVATE study of tumor treating fields (200 kHz) concomitant with weekly paclitaxel for platinum-resistant ovarian cancer (ENGOT-ov50/BGOG study groups)
Clinical Trials2019-07-01
Meta-analysis of toxicity data in thoracic and abdominal malignancies from: Clinical trials in tumor treating fields.
Journal of Clinical Oncology2019-05-20
INNOVATE-3: Phase 3 randomized, international study of tumor treating fields (200 kHz) concomitant with weekly paclitaxel for the treatment of platinum-resistant ovarian cancer.
Journal of Clinical Oncology2018-05-207 citations
INNOVATE: A phase II study of TTFields (200 kHz) concomitant with weekly paclitaxel for recurrent ovarian cancer—Updated safety and efficacy results.
Journal of Clinical Oncology2017-05-205 citations
Abstract B79: Translational study of tumor treating fields in combination with paclitaxel in ovarian cancer.
Clinical Cancer Research2016-01-151 citations